Overview

* Arcus Q2 2025 revenue rises sharply, beating analyst expectations, per LSEG data

* Co reports strong cash position of $927 mln to support pipeline advancement

* Arcus initiates key trials, with upcoming data presentations planned for fall 2025

Outlook

* Arcus expects 2025 GAAP revenue between $225 mln and $235 mln

* Company anticipates R&D expenses to decline starting Q4 2025

* Arcus has sufficient funds to support ongoing trials through pivotal readouts

* Company expects more mature ARC-20 data in fall 2025

Result Drivers

* REVENUE INCREASE - Driven by cumulative catch-up relating to pausing future development of etrumadenant and Gilead's license return

* PIPELINE ADVANCEMENT - Initiation of PEAK-1 and eVOLVE-RCC02 trials for casdatifan in ccRCC

* STRONG CASH POSITION - $927 mln in cash and equivalents to support pipeline progress

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $152 mln $31.50

Revenue mln (8

Analysts

)

Q2 $168 mln

Operatin

g

Expenses

Q2 -$8 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Arcus Biosciences Inc ( RCUS ) is $26.00, about 63.3% above its August 5 closing price of $9.55

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)